262 related articles for article (PubMed ID: 10837460)
1. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
2. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis.
Maeshima Y; Yerramalla UL; Dhanabal M; Holthaus KA; Barbashov S; Kharbanda S; Reimer C; Manfredi M; Dickerson WM; Kalluri R
J Biol Chem; 2001 Aug; 276(34):31959-68. PubMed ID: 11399763
[TBL] [Abstract][Full Text] [Related]
3. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.
Sudhakar A; Sugimoto H; Yang C; Lively J; Zeisberg M; Kalluri R
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4766-71. PubMed ID: 12682293
[TBL] [Abstract][Full Text] [Related]
4. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion.
Pedchenko V; Zent R; Hudson BG
J Biol Chem; 2004 Jan; 279(4):2772-80. PubMed ID: 14610079
[TBL] [Abstract][Full Text] [Related]
5. Distinct antitumor properties of a type IV collagen domain derived from basement membrane.
Maeshima Y; Colorado PC; Torre A; Holthaus KA; Grunkemeyer JA; Ericksen MB; Hopfer H; Xiao Y; Stillman IE; Kalluri R
J Biol Chem; 2000 Jul; 275(28):21340-8. PubMed ID: 10766752
[TBL] [Abstract][Full Text] [Related]
6. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.
Maeshima Y; Manfredi M; Reimer C; Holthaus KA; Hopfer H; Chandamuri BR; Kharbanda S; Kalluri R
J Biol Chem; 2001 May; 276(18):15240-8. PubMed ID: 11278365
[TBL] [Abstract][Full Text] [Related]
7. The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha Vbeta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation.
Pasco S; Monboisse JC; Kieffer N
J Biol Chem; 2000 Oct; 275(42):32999-3007. PubMed ID: 10934203
[TBL] [Abstract][Full Text] [Related]
8. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity.
Eikesdal HP; Sugimoto H; Birrane G; Maeshima Y; Cooke VG; Kieran M; Kalluri R
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):15040-5. PubMed ID: 18818312
[TBL] [Abstract][Full Text] [Related]
9. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells.
Shahan TA; Ziaie Z; Pasco S; Fawzi A; Bellon G; Monboisse JC; Kefalides NA
Cancer Res; 1999 Sep; 59(18):4584-90. PubMed ID: 10493512
[TBL] [Abstract][Full Text] [Related]
10. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
Hamano Y; Kalluri R
Biochem Biophys Res Commun; 2005 Jul; 333(2):292-8. PubMed ID: 15979458
[TBL] [Abstract][Full Text] [Related]
11. Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.
Silletti S; Kessler T; Goldberg J; Boger DL; Cheresh DA
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):119-24. PubMed ID: 11134507
[TBL] [Abstract][Full Text] [Related]
12. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.
Maeshima Y; Sudhakar A; Lively JC; Ueki K; Kharbanda S; Kahn CR; Sonenberg N; Hynes RO; Kalluri R
Science; 2002 Jan; 295(5552):140-3. PubMed ID: 11778052
[TBL] [Abstract][Full Text] [Related]
13. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin.
Hamano Y; Zeisberg M; Sugimoto H; Lively JC; Maeshima Y; Yang C; Hynes RO; Werb Z; Sudhakar A; Kalluri R
Cancer Cell; 2003 Jun; 3(6):589-601. PubMed ID: 12842087
[TBL] [Abstract][Full Text] [Related]
14. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas.
Caudroy S; Cucherousset J; Lorenzato M; Zahm JM; Martinella-Catusse C; Polette M; Birembaut P
Hum Pathol; 2004 Oct; 35(10):1218-22. PubMed ID: 15492988
[TBL] [Abstract][Full Text] [Related]
15. The antitumor properties of the alpha3(IV)-(185-203) peptide from the NC1 domain of type IV collagen (tumstatin) are conformation-dependent.
Floquet N; Pasco S; Ramont L; Derreumaux P; Laronze JY; Nuzillard JM; Maquart FX; Alix AJ; Monboisse JC
J Biol Chem; 2004 Jan; 279(3):2091-100. PubMed ID: 14583633
[TBL] [Abstract][Full Text] [Related]
16. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
17. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo.
Petitclerc E; Boutaud A; Prestayko A; Xu J; Sado Y; Ninomiya Y; Sarras MP; Hudson BG; Brooks PC
J Biol Chem; 2000 Mar; 275(11):8051-61. PubMed ID: 10713126
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.
Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L
Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.
Sudhakar A; Boosani CS
Pharm Res; 2008 Dec; 25(12):2731-9. PubMed ID: 18551250
[TBL] [Abstract][Full Text] [Related]
20. Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells.
Tarui T; Miles LA; Takada Y
J Biol Chem; 2001 Oct; 276(43):39562-8. PubMed ID: 11514539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
